Aerovate Therapeutics to Merge with Jade Biosciences

Yarrow Bioscience Completes Merger with VYNE Therapeutics

July 27, 2026

Biotechnology

Yarrow Bioscience announced the completion of its merger with VYNE Therapeutics, with the combined company operating as Yarrow Bioscience, Inc. The transaction follows previously announced private financings totaling approximately $200 million and includes the initiation of dosing in a Phase 2a/2b trial of YB-101 for Graves' disease and thyroid eye disease.

NextCure and Avere Therapeutics Announce Merger and $320 Million Financing to Create Oral IL-23 Biotech

July 17, 2026

Biotechnology

NextCure and Avere Therapeutics have entered into a definitive all-stock merger that will create a publicly traded biotechnology company focused on developing once-weekly oral therapies for inflammatory diseases driven by interleukin-23. The transaction is supported by a concurrent $320 million private placement led by Fairmount and Hansoh Pharmaceutical Group to fund key clinical milestones through Phase 2b and into Phase 3 development.

Boundless Bio and Serapha Bio Announce Merger and $230 Million Private Placement

June 25, 2026

Biotechnology

Boundless Bio and Serapha Bio entered into a definitive agreement to merge in an all-stock transaction. Serapha will combine with Boundless Bio, with the combined company expected to operate as Serapha Bio and trade on Nasdaq under ticker AATD, following a pre-closing $230 million private investment led by RA Capital Management and RTW Investments.

Rallybio Corporation to Acquire Avenzo Therapeutics in $215M Financing Deal

June 2, 2026

Biotechnology

Rallybio Corporation entered into a definitive merger agreement to acquire Avenzo Therapeutics, with the combined company expected to operate as Avenzo Therapeutics, Inc. and trade on Nasdaq under the ticker symbol AVZO. The transaction includes a concurrent, oversubscribed $215 million private placement with participation from healthcare institutional investors and mutual funds, and is expected to close in Q4 2026 subject to customary conditions.

Axcelis Technologies and Veeco Instruments to Combine in All-Stock Merger

October 1, 2025

IT Services

Axcelis Technologies and Veeco Instruments have entered into a definitive agreement to combine in an all-stock merger. The transaction is expected to close in the second half of 2026, subject to shareholder approvals, regulatory approvals, and customary closing conditions.

Welltower (Affiliate) to Acquire NorthStar Healthcare Income; TPG to Acquire Altus Power; Jade Biosciences to Merge with Aerovate Therapeutics (Plus KVAC/ Madera SPAC Merger)

March 18, 2025

Healthcare Services

The announcement flags multiple pending M&A actions in which NorthStar Healthcare Income is proposed to be acquired by an affiliate of Welltower for $3.03 per share in cash, Altus Power is proposed to be acquired by TPG for $5.00 per share in an all-cash deal, and Aerovate Therapeutics is proposed to merge with Jade Biosciences. It also references Keen Vision Acquisition Corp. in connection with a proposed merger with Madera Inc.